But it's logical to ask: What's Vertex's long-term story? Where will the company be in 10 years, for example? Let's find out. Image source: Getty Images. First, a bit of background on Vertex's CF ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its twice-daily cystic fibrosis medication ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

The US Army's first women to become Rangers ... An exclusive by the Associated Press reported that 26,000 images had been flagged for deletion. The online content purge is the latest in a series ...

The commercial satellite imaging company Maxar confirmed that it is suspending the sharing of US government-commissioned imagery with Ukraine, a move that severely constrains Ukrainian drone ...

At least 13 civilians were killed, and nine injured, in strikes on Yemen’s capital city of Sanaa. At least 11 others, including four children and one woman, were killed, and 14 injured, in a ...

The US Defence Department is erasing from its archives thousands of images of diversity, equity and inclusion to comply with White House orders to end those programmes across federal government.